These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1354 related articles for article (PubMed ID: 31585395)

  • 1. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
    Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
    Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
    Proto C; Ferrara R; Signorelli D; Lo Russo G; Galli G; Imbimbo M; Prelaj A; Zilembo N; Ganzinelli M; Pallavicini LM; De Simone I; Colombo MP; Sica A; Torri V; Garassino MC
    Cancer Treat Rev; 2019 May; 75():39-51. PubMed ID: 30954906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.
    Shafique M; Tanvetyanon T
    Expert Opin Biol Ther; 2019 Mar; 19(3):225-232. PubMed ID: 30657338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining chemotherapy with PD-1 blockade in NSCLC.
    Mathew M; Enzler T; Shu CA; Rizvi NA
    Pharmacol Ther; 2018 Jun; 186():130-137. PubMed ID: 29352857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
    PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward innovative combinational immunotherapy: A systems biology perspective.
    Li XT; Yang JJ; Wu YL; Hou J
    Cancer Treat Rev; 2018 Jul; 68():1-8. PubMed ID: 29775845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung cancer: potential targets for immunotherapy.
    Tartour E; Zitvogel L
    Lancet Respir Med; 2013 Sep; 1(7):551-63. PubMed ID: 24461616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.